Paul Brannelly
2013 - Karyopharm Therapeutics
In 2013, Paul Brannelly earned a total compensation of $2M as Senior Vice President, Finance and Administration at Karyopharm Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $117,960 |
|---|---|
| Option Awards | $1,702,879 |
| Salary | $160,505 |
| Other | $4,614 |
| Total | $1,985,958 |
Brannelly received $1.7M in option awards, accounting for 86% of the total pay in 2013.
Brannelly also received $118K in non-equity incentive plan, $160.5K in salary and $4.6K in other compensation.
Rankings
In 2013, Paul Brannelly's compensation ranked 3,922nd out of 12,286 executives tracked by ExecPay. In other words, Brannelly earned more than 68.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,922 out of 12,286 | 68th |
Division Manufacturing | 1,326 out of 4,612 | 71st |
Major group Chemicals And Allied Products | 360 out of 1,466 | 75th |
Industry group Drugs | 252 out of 1,160 | 78th |
Industry Pharmaceutical Preparations | 205 out of 890 | 77th |
Source: SEC filing on April 28, 2014.
Brannelly's colleagues
We found two more compensation records of executives who worked with Paul Brannelly at Karyopharm Therapeutics in 2013.